In the wake of the massive allegations of fraud by resveratrol researcher Dipak Das, other researchers in the field are clearly trying to distance themselves from the University of Connecticut scientist. Nir Barzilai told us yesterday, for example, that despite Das seemingly’ impressive publication record, “Rome was not built on Dr. Das.”
Many Retraction Watch readers will now be familiar with the case of Dipak Das, the resveratrol researcher about whom the University of Connecticut issued a voluminous report yesterday — summary here — detailing 145 counts of data fabrication and falsification. This has been a fast-moving story, so we wanted to highlight a number of updates to our original post, and offer a few more.
The Office of Research Integrity has thrown a heavy book at Bengu Sezen, a former chemist at Columbia University, alleging that school and agency investigators turned up 21 instances of research misconduct by the disgraced scientist.
In the world of scientific misconduct, it’s often worth keeping track of what happens to scientists whose papers were retracted because of falsified or otherwise fraudulent results.
Take the case of Hung-Shu Chang. Last week, the the federal Office of Research Integrity announced that it had closed its investigation into the scientist’s misdeeds. Chang was a visiting postdoctoral researcher from Taiwan who in 2005 had come to the renowned Skinner Laboratory at Washington State University to study the effects of endocrine disruptors — a class of compounds that includes BPA and which have been shown to disrupt the action of hormones — on sex cells.
Chang was accused of falsifying data in a 2006 paper in Endocrinology — later retracted — reporting the damaging effects of vinclozolin, a fungicide used to protect vineyards, on the genetic integrity of sperm cells.